Peptide Library

Human study PLS-00089

A possible role for mitochondrial-derived peptides humanin and MOTS-c in patients with Q fever fatigue syndrome and chronic fatigue syndrome.

Cross-sectional study · 40 participants enrolled · not included in the assessments (wrong compound)

Version 1 · published November 7, 2026 · evidence through November 7, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

Only the abstract was available. Essential methods may be missing, which limits what can be judged.

Reports of this study

Every publication, registration and abstract describing this one study. Participants are counted once.

  • A possible role for mitochondrial-derived peptides humanin and MOTS-c in patients with Q fever fatigue syndrome and chronic fatigue syndrome.primary · Journal of translational medicine · 2019-05-14 · PMID 31088495 · DOI

Design and participants

Design
Cross-sectional study
Population
Age- and sex-matched adults: Q fever fatigue syndrome patients, chronic fatigue syndrome patients, asymptomatic Q fever seropositive controls and healthy controls.
Conditions
Q fever fatigue syndrome, Chronic fatigue syndrome
Planned enrollment (registry)
Not reported
Enrolled
40
Randomized
Not reported
Completed follow-up
Not reported
Funding
Non-U.S. government research support (publication type); details not stated.

Intervention and comparator

What each group received. Related peptides, analogs and combinations are never treated as the compound itself.

    What the authors reported

    As stated in the sources. This is the authors’ account, not Peptide Library’s assessment.

    Adverse events

    None reported. That is not evidence of safety.

    Monitoring: Not applicable; no compound was administered.

    The authors concluded (paraphrased): Expression of the MOTS-c and humanin coding genes is decreased in CFS, QFS and, to a lesser extent, in Q fever seropositive controls, with decreased humanin production. These peptides may matter in the pathophysiology of QFS and CFS.

    Peptide Library’s assessment

    An automated assessment, made by AI separately from the authors’ conclusions and not reviewed by a person. How risk of bias is assessed.

    Limitations

    • other: Outcomes are gene expression and peptide levels, not clinical outcomes.
    • small or imprecise: Only 10 participants per group, 40 in total.
    • confounding: Groups were matched only on age and sex; other confounders were not described in the abstract.
    • abstract only: Appraisal is based on the abstract alone; full methods were not available in the record.
    • inappropriate endpoint: The outcome was gene expression (a transcriptomic surrogate), not a clinical outcome, and no MOTS-c was administered.

    No risk-of-bias assessment has been published for this study’s results.

    Claims this study informs

    Where each value comes from

    • arms: PMID 31088495, abstract (Methods, sentence 1) · extracted by AI (automated, not verified by a person) · abstract only
    • author_conclusion: PMID 31088495, abstract (Conclusions, sentences 1-2) · extracted by AI (automated, not verified by a person) · abstract only
    • design: PMID 31088495, abstract (Methods, sentences 1-2) · extracted by AI (automated, not verified by a person) · abstract only
    • limitations: PMID 31088495, abstract (Methods, sentences 1-2) · extracted by AI (automated, not verified by a person) · abstract only
    • outcomes: PMID 31088495, abstract (Results, sentence 1) · extracted by AI (automated, not verified by a person) · abstract only
    • participants: PMID 31088495, abstract (Methods, sentence 1) · extracted by AI (automated, not verified by a person) · abstract only
    • population: PMID 31088495, abstract (Methods, sentence 1) · extracted by AI (automated, not verified by a person) · abstract only
    • results: PMID 31088495, abstract (Results, sentence 1) · extracted by AI (automated, not verified by a person) · abstract only

    • Version 1 · published November 7, 2026 · evidence through November 7, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

    These assessments describe published research. Records marked automated were produced by AI under the published methodology and have not been reviewed by a person; they can contain errors. None of this is medical advice, not a statement about any product’s safety for human use, and not a regulatory approval. Peptide Library’s vendor and partner relationships play no part in them (editorial independence).